Stockreport

Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflu...

Phathom Pharmaceuticals, Inc.  (PHAT) 
Last phathom pharmaceuticals, inc. earnings: 3/19 08:31 am Check Earnings Report
PDF nighttime gastroesophageal reflux disease (GERD) symptoms in patients treated with VOQUEZNA, including clinically meaningful increases in heartburn-free nights observed [Read more]